Therapy Areas: Allergy
FDA Approves Optinose's Xhance Nasal Spray for the Treatment of Nasal Polyps
19 September 2017 - - Yardley, Pennsylvania-based otolaryngology and allergy therapeutics developer Optinose has received approval from the US Food and Drug Administration (FDA) of its New Drug Applic...
ALK-Abelló announces successful Phase III trial for tree allergy SLIT-tablet
15 September 2017 - ALK-Abelló A/S (ALK)(CPH:ALKB), a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment, reported on Thursday the successful ...
Pulmonary Drug Delivery Systems Market to Reach USD 55.1bn by 2025, Grand View Research Forecasts
14 September 2017 - - The global pulmonary drug delivery devices/systems market is expected to reach USD 55.1bn by 2025, according to a new report by US based market research and consul...
Geom Therapeutics, NIAID Partner to Conduct Study of Novel Cephalosporin Antibiotic
14 September 2017 - - US-based antibiotic developer Geom Therapeutics, Inc. has signed a clinical trial agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the Na...
NIAID, Zavante Partner in Clinical Trial of Zolyd as Bacterial Pneumonia Treatment
11 September 2017 - - US-based late clinical-stage biopharmaceutical company Zavante Therapeutics, Inc. has signed a clinical trial agreement with the National Institute of Allergy and Infectious Dise...
NIAID, Zavante Partner in Clinical Trial of Zolyd as Bacterial Pneumonia Treatment
11 September 2017 - - US-based late clinical-stage biopharmaceutical company Zavante Therapeutics, Inc. has signed a clinical trial agreement with the National Institute of Allergy and Infectious Dise...